Cancer Chemotherapy by Novel Bio-active Natural Products: Looking Towards the Future

2019 ◽  
Vol 15 (1) ◽  
pp. 37-49
Author(s):  
Om Prakash ◽  
Shazia Usmani ◽  
Ruchi Singh ◽  
Debarshi K. Mahapatra ◽  
Amresh Gupta
Keyword(s):  
Clinical Trials ◽  
Natural Products ◽  
Cancer Drug ◽  
The Novel ◽  
Current Review ◽  
Chronic Disorder ◽  
Anti Cancer ◽  
The Us ◽  
Plant Sources ◽  
Active Natural

Background: Cancer is the second leading cause of death globally and accounted for 8.8 million deaths annually in humans. Lung, prostate, colorectal, stomach and liver cancer are the most common types of cancer in men, while breast, colorectal, lung, cervix and stomach cancer are the most common among women. Numerous drugs that the US Food and Drug Administration (FDA) have approved for use in cancer therapy are derived from plants, including taxanes such as paclitaxel and vinca alkaloids such as vincristine and vinblastine. Still, there is an intense need for a search for numerous bioactive sources to develop a novel anti-cancer drug to overcome this chronic disorder. About more than thirty plants derived natural products have been isolated till date and are currently under clinical trials. As per literature survey from various journals and texts has been found to be novel medicinal agents from bioactive sources are clinically active against various types of cancer cells. Conclusion: Current review has been highlighted on the novel medicinal agents from plant sources have potential effects against many types of cancer, which have been supported by clinical trials. The main findings of these active novel medicinal agents were also summarized and discussed here.

scholarly journals F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity

Leukemia ◽  
2013 ◽  
Vol 27 (11) ◽  
pp. 2139-2148 ◽  
Author(s):  
A Kruczynski ◽  
A Pillon ◽  
L Créancier ◽  
I Vandenberghe ◽  
B Gomes ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cancer Drug ◽  
Anti Cancer

Facile Synthetic Protocols for the preparation of New Impurities in Pemetrexed Disodium Heptahydrate as an Anti-Cancer Drug

2021 ◽  
Vol 18 ◽  
Author(s):  
Rama Mohana Reddy Jaggavarapu ◽  
Venkatanarayana Muvvala ◽  
Ghojala Venkatareddy ◽  
Ravi Kumar Cheedarala
Keyword(s):  
Quality Control ◽  
Spectral Analysis ◽  
1H Nmr ◽  
Structure Elucidation ◽  
Research Work ◽  
Synthetic Methods ◽  
Cancer Drug ◽  
The Novel ◽  
Anti Cancer ◽  
Pemetrexed Disodium

: A facile synthetic protocols were employed to prepare process-related impurities associated with the synthesis of pemetrexed disodium heptahydrate, Alimta. The research work is described for the development of the novel synthetic methods and their structure elucidation of Pemetrexed glutamide, N-methyl pemetrexed, and N-methyl pemetrexed glutamide impurities. The listed impurities were deduced through spectral analysis such as 1H-NMR, 13CNMR, and HRMS. The target compounds can be used as the reference substances for the quality control.

scholarly journals Anticancer Agents from Diverse Natural Sources

2014 ◽  
Vol 9 (11) ◽  
pp. 1934578X1400901 ◽  
Author(s):  
Jabeena Khazir ◽  
Darren L. Riley ◽  
Lynne A. Pilcher ◽  
Pieter De-Maayer ◽  
Bilal Ahmad Mir
Keyword(s):  
Clinical Trials ◽  
Natural Products ◽  
Anticancer Agents ◽  
Marine Organisms ◽  
New Drugs ◽  
Human Diseases ◽  
Cancer Drugs ◽  
Natural Sources ◽  
Anti Cancer ◽  
Ancient Times

This review attempts to portray the discovery and development of anticancer agents/drugs from diverse natural sources. Natural molecules from these natural sources including plants, microbes and marine organisms have been the basis of treatment of human diseases since the ancient times. Compounds derived from nature have been important sources of new drugs and also serve as templates for synthetic modification. Many successful anti-cancer drugs currently in use are naturally derived or their analogues and many more are under clinical trials. This review aims to highlight the invaluable role that natural products have played, and continue to play, in the discovery of anticancer agents.

Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration

2004 ◽  
Vol 22 (22) ◽  
pp. 4626-4631 ◽  
Author(s):  
Lilia Talarico ◽  
Gang Chen ◽  
Richard Pazdur
Keyword(s):  
Clinical Trials ◽  
Cancer Patients ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
The Elderly ◽  
New Drugs ◽  
Cancer Drug ◽  
Cancer Therapies ◽  
Age Related ◽  
The Us

Purpose To analyze the age-related enrollment of cancer patients onto registration trials of new drugs or new indications approved by the US Food and Drug Administration from 1995 to 2002. Patients and Methods This study involved retrospective analyses of demographic data of cancer patients enrolled onto registration trials. The data on 28,766 cancer patients from 55 registration trials were analyzed according to age distributions of ≥ 65, ≥ 70, and ≥ 75 years. The rates of enrollment in each age group for each cancer were compared with the corresponding rates in the US cancer population. The age distributions of the US cancer population were derived from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute for the period 1995 to 1999 based on the 2000 US Census. Results The proportions of the overall patient populations aged ≥ 65, ≥ 70, and ≥ 75 years were 36%, 20%, and 9% compared with 60%, 46%, and 31%, respectively, in the US cancer population. Statistically significant under-representation of the elderly (P < .001) was noted in registration trials for all cancer treatment except for breast cancer hormonal therapies. Patients aged ≥ 70 years accounted for most of the under-representation. Conclusion Elderly were under-represented in the registration trials of new cancer therapies. Various strategies may be needed to evaluate cancer therapies for the elderly in prospective clinical trials and to improve cancer care in the elderly population.

scholarly journals Defining desirable natural product derived anticancer drug space: optimization of molecular physicochemical properties and ADMET attributes

ADMET & DMPK ◽  
2016 ◽  
Vol 4 (2) ◽  
pp. 98 ◽  
Author(s):  
Deepika Singh
Keyword(s):  
Hydrogen Bond ◽  
Natural Products ◽  
Physicochemical Properties ◽  
Natural Product ◽  
Aqueous Solubility ◽  
Cancer Drug ◽  
Log P ◽  
Drug Candidates ◽  
Anti Cancer ◽  
Property Space

<p class="ADMETabstracttext">As part of our endeavor to enhance survival of natural product derived drug candidates and to guide the medicinal chemist to design higher probability space for success in the anti cancer drug development area, we embarked on a detailed study of the property space for a collection of natural product derived anti cancer molecules. We carried out a comprehensive analysis of properties for 24 natural products derived anti cancer drugs including clinical development candidates and a set of 27 natural products derived anti cancer lead compounds. In particular, we focused on understanding the interplay among eight physicochemical properties including like partition coefficient (log P), distribution coefficient at pH=7.4 (log D), topological polar surface area (TPSA), molecular weight (MW), aqueous solubility (log S), number of hydrogen bond acceptors (HBA), number of hydrogen bond donors (HBD) and number of rotatable bonds (n<sub>Rot</sub>) crucial for drug design and  relationships between physicochemical properties, ADME (absorption, distribution, metabolism, and elimination) attributes, and in silico toxicity profile for these two sets of compounds. This analysis provides guidance for the chemist to modify the existing natural product scaffold or designing of new anti cancer molecules in a property space with increased probability of success and may lead to the identification of druglike candidates with favorable safety profiles that can successfully test hypotheses in the clinic.</p>

scholarly journals Marine natural products

2017 ◽  
Vol 34 (3) ◽  
pp. 235-294 ◽  
Author(s):  
John W. Blunt ◽  
Brent R. Copp ◽  
Robert A. Keyzers ◽  
Murray H. G. Munro ◽  
Michèle R. Prinsep
Keyword(s):  
Natural Products ◽  
Absolute Configuration ◽  
Marine Natural Products ◽  
Cancer Drug ◽  
Anti Cancer ◽  
New Compounds

This review of marine natural products for 2015 describes 1340 new compounds and reports structural revisions or assignments of absolute configuration for previously reported compounds. Other aspects of marine natural products research over the three sesquidecades from 1971 are also examined and contrasted against the 2015 discovery of the source of ET-743, also known as the anti-cancer drug Yondelis®(trabectedin).

Sign in / Sign up

Export Citation Format

Share Document